TenX Keane Acquisition
Why Robinhood?
You can watch TENK and buy or sell other stocks, ETFs, and their options commission-free!About TENK
Citius Oncology, Inc. is a biopharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
TENK Key Statistics
Stock Snapshot
The current TenX Keane Acquisition(TENK) stock price is $1.00, with a market capitalization of 84.77M. The stock trades at a price-to-earnings (P/E) ratio of -3.28.
On 2026-03-10, TenX Keane Acquisition(TENK) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for TenX Keane Acquisition(TENK) stock has reached 0, versus its average volume of 601.72K.
Over the past 52 weeks, TenX Keane Acquisition(TENK) stock has traded between a high of $6.19 and a low of $0.55.
Over the past 52 weeks, TenX Keane Acquisition(TENK) stock has traded between a high of $6.19 and a low of $0.55.
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.